Nepal Pioneer Worksite Intervention Study to lower cardio-metabolic risk factors: design and protocol.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
28 02 2019
Historique:
received: 24 08 2018
accepted: 19 02 2019
entrez: 2 3 2019
pubmed: 2 3 2019
medline: 18 12 2019
Statut: epublish

Résumé

To increase cardiovascular disease prevention efforts, worksite interventions can promote healthy food choices, facilitate health education, increase physical activity and provide social support. This pioneer study will measure the effectiveness of a cafeteria and a behavioral intervention on cardio-metabolic risk in a worksite in Nepal. The Nepal Pioneer Worksite Intervention Study is a two-step intervention study conducted in Dhulikhel Hospital in eastern Nepal. In the first step, we will assess the effectiveness of a 6-month cafeteria intervention on cardio-metabolic risk using a pre-post design. In the second step, we will conduct a 6-month, open-masked, two-arm randomized trial by allocating half of the participants to an individual behavioral intervention based on the 'diabetes prevention program' for the prevention of cardio-metabolic risk. We will recruit 366 full time employees with elevated blood pressure, fasting blood sugar, or glycosylated haemoglobin (HbA1c). At baseline, we will measure their demographic variables, lifestyle factors, anthropometry, fasting blood sugar, HbA1c,and lipid profiles. We will measure cardio-metabolic outcomes at 6 months, 12 months, and 18 months. At 12 months, we will compare the proportion of participants who have attained two or more cardio-metabolic risk factor reduction goals (HbA1 This pioneer study will estimate the effect of environmental-level changes on lowering cardio-metabolic risks; and added benefit of an individual-level dietary intervention. If the study demonstrates a significant effect, a scaled up approach could produce an important reduction in cardiovascular disease burden through environmental and individual level prevention programs in Nepal and similar worksites worldwide. The trial was retrospectively registered on clincaltrials.gov (Identification Member: NCT03447340 ; Date of Registration: February 27, 2018).

Sections du résumé

BACKGROUND
To increase cardiovascular disease prevention efforts, worksite interventions can promote healthy food choices, facilitate health education, increase physical activity and provide social support. This pioneer study will measure the effectiveness of a cafeteria and a behavioral intervention on cardio-metabolic risk in a worksite in Nepal.
METHODS
The Nepal Pioneer Worksite Intervention Study is a two-step intervention study conducted in Dhulikhel Hospital in eastern Nepal. In the first step, we will assess the effectiveness of a 6-month cafeteria intervention on cardio-metabolic risk using a pre-post design. In the second step, we will conduct a 6-month, open-masked, two-arm randomized trial by allocating half of the participants to an individual behavioral intervention based on the 'diabetes prevention program' for the prevention of cardio-metabolic risk. We will recruit 366 full time employees with elevated blood pressure, fasting blood sugar, or glycosylated haemoglobin (HbA1c). At baseline, we will measure their demographic variables, lifestyle factors, anthropometry, fasting blood sugar, HbA1c,and lipid profiles. We will measure cardio-metabolic outcomes at 6 months, 12 months, and 18 months. At 12 months, we will compare the proportion of participants who have attained two or more cardio-metabolic risk factor reduction goals (HbA1
DISCUSSION
This pioneer study will estimate the effect of environmental-level changes on lowering cardio-metabolic risks; and added benefit of an individual-level dietary intervention. If the study demonstrates a significant effect, a scaled up approach could produce an important reduction in cardiovascular disease burden through environmental and individual level prevention programs in Nepal and similar worksites worldwide.
TRIAL REGISTRATION
The trial was retrospectively registered on clincaltrials.gov (Identification Member: NCT03447340 ; Date of Registration: February 27, 2018).

Identifiants

pubmed: 30819098
doi: 10.1186/s12872-019-1025-3
pii: 10.1186/s12872-019-1025-3
pmc: PMC6393979
doi:

Banques de données

ClinicalTrials.gov
['NCT03447340']

Types de publication

Clinical Trial Protocol Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

48

Subventions

Organisme : NIEHS NIH HHS
ID : DP1 ES025459
Pays : United States

Références

Ann Intern Med. 2014 Oct 21;161(8):568-78
pubmed: 25155549
PLoS Med. 2007 Aug;4(8):e261
pubmed: 17760498
Scand J Work Environ Health. 2010 May;36(3):202-15
pubmed: 20066386
Occup Med (Lond). 2014 Jan;64(1):8-12
pubmed: 24280187
Am J Prev Med. 2009 Oct;37(4):340-57
pubmed: 19765507
Circulation. 2009 Oct 27;120(17):1725-41
pubmed: 19794121
Circulation. 2014 Jun 24;129(25 Suppl 2):S76-99
pubmed: 24222015
J Phys Act Health. 2009 Nov;6(6):790-804
pubmed: 20101923
BMJ. 2004 Apr 3;328(7443):781
pubmed: 15070612
Am J Prev Med. 2009 Oct;37(4):330-9
pubmed: 19765506
Biometrics. 1997 Sep;53(3):937-47
pubmed: 9290224
Diabetes. 1997 Apr;46(4):701-10
pubmed: 9075814
Biometrics. 1986 Mar;42(1):121-30
pubmed: 3719049
Am J Orthod Dentofacial Orthop. 2005 Dec;128(6):681-5; discussion 686
pubmed: 16360902
Popul Health Manag. 2013 Feb;16(1):14-21
pubmed: 23113636
Am J Prev Med. 2003 Oct;25(3 Suppl 2):172-83
pubmed: 14552942
Am J Prev Med. 2005 Jul;29(1):61-70
pubmed: 15958254
Lancet. 2011 Feb 19;377(9766):680-9
pubmed: 21269677
Prim Care Diabetes. 2012 Apr;6(1):3-9
pubmed: 21616737
Am J Health Promot. 1997 Mar-Apr;11(4):290-307
pubmed: 10165522
Am J Occup Ther. 2012 Jul-Aug;66(4):387-8
pubmed: 22742685
Int J Vasc Med. 2013;2013:786801
pubmed: 24163770
Diabetes Care. 2007 Jul;30(7):1753-7
pubmed: 17429059
Am J Health Promot. 2005 Jan-Feb;19(3):167-93
pubmed: 15693346
MMWR Recomm Rep. 2005 Oct 7;54(RR-10):1-12
pubmed: 16261131
Diabetes Care. 2002 Dec;25(12):2165-71
pubmed: 12453955
Ann Intern Med. 2014 Oct 21;161(8):587-93
pubmed: 25155419
J Assoc Physicians India. 2005 Sep;53:759-63
pubmed: 16334618

Auteurs

Archana Shrestha (A)

Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, USA. deararchana@gmail.com.

Dipesh Tamrakar (D)

Department of Community Medicine, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
Department of Community Programs, Dhulikhel Hospital-Kathmandu University Hospital, Dhulikhel, Nepal.

Biraj Man Karmacharya (BM)

Department of Community Medicine, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
Department of Community Programs, Dhulikhel Hospital-Kathmandu University Hospital, Dhulikhel, Nepal.

Abha Shrestha (A)

Department of Community Programs, Dhulikhel Hospital-Kathmandu University Hospital, Dhulikhel, Nepal.

Rajeev Shrestha (R)

Department of Pharmacology, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.

Rajendra Dev Bhatta (RD)

Department of Biochemistry, Dhulikhel Hospital- Kathmandu University Hospital, Dhulikhel, Nepal.

Prajjwal Pyakurel (P)

Department of Community Medicine, BP Koirala Institute of Health Science, Dharan, Nepal.

Polyna Khudyakov (P)

Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, USA.

Vasanti Malik (V)

Department of Nutrition, Harvard TH Chan School of Public Health, Boston, USA.

Josiemer Mattei (J)

Department of Nutrition, Harvard TH Chan School of Public Health, Boston, USA.

Donna Spiegelman (D)

Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, USA.
Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, USA.
Department of Nutrition, Harvard TH Chan School of Public Health, Boston, USA.
Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH